Antonio Giordano, Breast Medical Oncologist at Harvard Medical School, shared a post on X:
“New way to target cell cycle. Cycling through Innovation ESMO – Eur. Oncology ESMOASIA24 with Drs. Lee and Naito.
Exciting new drugs to target CDK4, CDK2, and more in HR+/Her2- MBC.
Taking 2L PFS closer to 12 months and away from chemo.”
